IL108750A - Pharmaceutical cognition enhancing compositions containing 1,3-dialiphatic-8-(phenylalkyl or ludanyl) xanthines as selective adenosine receptor agents - Google Patents
Pharmaceutical cognition enhancing compositions containing 1,3-dialiphatic-8-(phenylalkyl or ludanyl) xanthines as selective adenosine receptor agentsInfo
- Publication number
- IL108750A IL108750A IL10875094A IL10875094A IL108750A IL 108750 A IL108750 A IL 108750A IL 10875094 A IL10875094 A IL 10875094A IL 10875094 A IL10875094 A IL 10875094A IL 108750 A IL108750 A IL 108750A
- Authority
- IL
- Israel
- Prior art keywords
- ludanyl
- dialiphatic
- xanthines
- phenylalkyl
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2350193A | 1993-02-26 | 1993-02-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL108750A0 IL108750A0 (en) | 1994-05-30 |
| IL108750A true IL108750A (en) | 2000-09-28 |
Family
ID=21815459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL10875094A IL108750A (en) | 1993-02-26 | 1994-02-23 | Pharmaceutical cognition enhancing compositions containing 1,3-dialiphatic-8-(phenylalkyl or ludanyl) xanthines as selective adenosine receptor agents |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5840729A (fr) |
| EP (1) | EP0686155B1 (fr) |
| JP (1) | JPH08512281A (fr) |
| KR (1) | KR100315898B1 (fr) |
| CN (1) | CN1041418C (fr) |
| AT (1) | ATE169019T1 (fr) |
| AU (1) | AU680241B2 (fr) |
| CA (1) | CA2155130C (fr) |
| DE (1) | DE69412073T2 (fr) |
| DK (1) | DK0686155T3 (fr) |
| ES (1) | ES2120025T3 (fr) |
| HU (1) | HUT72677A (fr) |
| IL (1) | IL108750A (fr) |
| MX (1) | MX9401406A (fr) |
| NO (1) | NO311920B1 (fr) |
| NZ (1) | NZ262984A (fr) |
| TW (1) | TW261532B (fr) |
| WO (1) | WO1994019349A1 (fr) |
| ZA (1) | ZA941176B (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998041237A1 (fr) * | 1997-03-18 | 1998-09-24 | Fujisawa Pharmaceutical Co., Ltd. | Medicaments pour la prevention et la therapie de l'hyperphosphatemie |
| PL204628B1 (pl) | 1998-06-02 | 2010-01-29 | Osi Pharmaceuticals | Pochodna pirolo[2,3d]pirymidyny, jej zastosowanie i sposoby wytwarzania tej pochodnej i preparaty farmaceutyczne |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US20020115635A1 (en) * | 2001-02-21 | 2002-08-22 | Pnina Fishman | Modulation of GSK-3beta activity and its different uses |
| EP1450811B1 (fr) | 2001-11-30 | 2009-10-21 | OSI Pharmaceuticals, Inc. | Composés specifiques aux recepteurs A1 et A3 de l'adenosine et leur utilisations |
| CA2471059C (fr) | 2001-12-20 | 2011-04-26 | Osi Pharmaceuticals, Inc. | Composes pyrimidine antagonistes selectifs des recepteurs a<sb>2b</sb>, leur synthese et leur utilisation |
| AU2003239472A1 (en) * | 2002-05-15 | 2003-12-02 | Genzyme Corporation | Synthesis of benzonitriles and benzimidates |
| WO2004086047A2 (fr) * | 2003-03-28 | 2004-10-07 | Bayer Healthcare Ag | Agents diagnostiques et therapeutiques de maladies associees a adenosine a1 du recepteur couple a la proteine g (adora1) |
| WO2005056016A1 (fr) * | 2003-12-09 | 2005-06-23 | Kyowa Hakko Kogyo Co., Ltd. | Agent preventif et/ou therapeutique pour un dysfonctionnement cerebral severe |
| US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7795427B2 (en) * | 2006-02-14 | 2010-09-14 | New York University | Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3843117A1 (de) * | 1988-12-22 | 1990-06-28 | Boehringer Ingelheim Kg | Neue xanthinderivate mit adenosin-antagonistischer wirkung |
| US5047534A (en) * | 1990-03-26 | 1991-09-10 | Merrell Dow Pharmaceuticals Inc. | Selective adenosine receptor agents |
| JPH0455150A (ja) * | 1990-06-22 | 1992-02-21 | Takata Kk | 助手席用エアバッグ装置 |
| DE4019892A1 (de) * | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
| US5087827A (en) * | 1991-02-11 | 1992-02-11 | Tektronix, Inc. | Variable voltage transition circuit |
| US5208240A (en) * | 1991-03-12 | 1993-05-04 | Merrell Dow Pharmaceuticals Inc. | 8-substituted purines as selective adenosine receptor agents |
| US5281607B1 (en) * | 1992-10-08 | 1998-05-19 | Univ New York | Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases |
-
1994
- 1994-01-27 DE DE69412073T patent/DE69412073T2/de not_active Expired - Fee Related
- 1994-01-27 ES ES94910661T patent/ES2120025T3/es not_active Expired - Lifetime
- 1994-01-27 HU HU9502495A patent/HUT72677A/hu unknown
- 1994-01-27 JP JP6518986A patent/JPH08512281A/ja active Pending
- 1994-01-27 NZ NZ262984A patent/NZ262984A/en unknown
- 1994-01-27 US US08/500,991 patent/US5840729A/en not_active Expired - Fee Related
- 1994-01-27 KR KR1019950703577A patent/KR100315898B1/ko not_active IP Right Cessation
- 1994-01-27 EP EP94910661A patent/EP0686155B1/fr not_active Expired - Lifetime
- 1994-01-27 AT AT94910661T patent/ATE169019T1/de not_active IP Right Cessation
- 1994-01-27 WO PCT/US1994/001009 patent/WO1994019349A1/fr active IP Right Grant
- 1994-01-27 DK DK94910661T patent/DK0686155T3/da active
- 1994-01-27 AU AU62968/94A patent/AU680241B2/en not_active Ceased
- 1994-01-27 CN CN94191309A patent/CN1041418C/zh not_active Expired - Fee Related
- 1994-01-27 CA CA002155130A patent/CA2155130C/fr not_active Expired - Fee Related
- 1994-02-21 ZA ZA941176A patent/ZA941176B/xx unknown
- 1994-02-22 TW TW083101485A patent/TW261532B/zh active
- 1994-02-23 IL IL10875094A patent/IL108750A/xx not_active IP Right Cessation
- 1994-02-24 MX MX9401406A patent/MX9401406A/es not_active IP Right Cessation
-
1995
- 1995-08-25 NO NO19953353A patent/NO311920B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HU9502495D0 (en) | 1995-10-30 |
| NO311920B1 (no) | 2002-02-18 |
| AU6296894A (en) | 1994-09-14 |
| CA2155130A1 (fr) | 1994-09-01 |
| TW261532B (fr) | 1995-11-01 |
| ZA941176B (en) | 1994-09-20 |
| NO953353L (no) | 1995-08-25 |
| DK0686155T3 (da) | 1999-02-01 |
| DE69412073D1 (de) | 1998-09-03 |
| DE69412073T2 (de) | 1999-02-18 |
| EP0686155B1 (fr) | 1998-07-29 |
| HUT72677A (en) | 1996-05-28 |
| JPH08512281A (ja) | 1996-12-24 |
| NZ262984A (en) | 1997-05-26 |
| KR100315898B1 (ko) | 2002-02-28 |
| EP0686155A1 (fr) | 1995-12-13 |
| IL108750A0 (en) | 1994-05-30 |
| CA2155130C (fr) | 1994-09-01 |
| CN1118599A (zh) | 1996-03-13 |
| CN1041418C (zh) | 1998-12-30 |
| ATE169019T1 (de) | 1998-08-15 |
| WO1994019349A1 (fr) | 1994-09-01 |
| AU680241B2 (en) | 1997-07-24 |
| ES2120025T3 (es) | 1998-10-16 |
| NO953353D0 (no) | 1995-08-25 |
| US5840729A (en) | 1998-11-24 |
| MX9401406A (es) | 1994-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL117848A0 (en) | Novel compounds a process for their production and pharmacetical compositions containing same | |
| IL108520A0 (en) | Imidazopyridine derivatives, processes for the preparation thereof, and pharmaceutical compositions containing them | |
| IL132153A0 (en) | Novel compounds | |
| NO952229D0 (no) | Anvendelse av karbamazepin og okskarbazepin ved behandling av neurologiske lesjoner relatert til traumatiske skader | |
| HU9502065D0 (en) | Application of carbamazepine and oxcarbazepine in the treatment of parkinson's disease and parkinsonian syndromes | |
| ZA946142B (en) | Therapeutic heterocycles | |
| IL108750A (en) | Pharmaceutical cognition enhancing compositions containing 1,3-dialiphatic-8-(phenylalkyl or ludanyl) xanthines as selective adenosine receptor agents | |
| EE9900315A (et) | Pürrolo[3,4-d]pürimidinooni derivaadid ja nende kasutamine ravimitena | |
| IL124091A (en) | Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the preparation of pharmaceutical compositions for the treatment of amyotrophic lateral sclerosis and pharmaceutical compositions containing it | |
| IL112999A0 (en) | Crystalline salts of 2,3,4,5- tetrahydro -1h-3-benzazepine compounds, their preparation and pharmaceutical compositions containing them | |
| ES2006619A6 (es) | Un metodo para preparar derivados de piridil-y pirimidil-piperazinas. | |
| FI932490A (fi) | Underenhetsvaccin mot Neisseria meningitidis-infektioner och motsvarande underenheter i rent tillstaond | |
| GB9507883D0 (en) | Compounds | |
| IL104817A0 (en) | Sugar derivatives of macrolides | |
| IL107917A0 (en) | Triazoloquinazolines, their preparation and their use as medicaments | |
| IL108283A0 (en) | Use of riluzole for promoting restoration following radiation | |
| MX9802000A (es) | Sales de adicion de acido de compuestos de 2,3,4,5-tetrahidro-1h-3-benzacepina. | |
| NZ304823A (en) | Beta carboline derivatives and medicaments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| RH1 | Patent not in force |